307 related articles for article (PubMed ID: 37186270)
1. Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study.
Khan AA; AbuAlrob H; M'Hiri I; Ali DS; Dandurand K; Said H; Alkassem H; Hakami Y; Hweija I; Iqbal S; Romanovschi M; Mehmood S; Zariffeh H; Guyatt G; Ibrahim Q; Brignardello-Petersen R; Syed HI
Endocrine; 2023 Jun; 80(3):647-657. PubMed ID: 37186270
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension.
Hans D; McDermott M; Huang S; Kim M; Shevroja E; McClung M
Osteoporos Int; 2023 Jun; 34(6):1075-1084. PubMed ID: 36862192
[TBL] [Abstract][Full Text] [Related]
3. Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial.
Cosman F; McMahon D; Dempster D; Nieves JW
J Bone Miner Res; 2020 Feb; 35(2):219-225. PubMed ID: 31419313
[TBL] [Abstract][Full Text] [Related]
4. Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.
Shane E; Shiau S; Recker RR; Lappe JM; Agarwal S; Kamanda-Kosseh M; Bucovsky M; Stubby J; Cohen A
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1528-e1540. PubMed ID: 34849989
[TBL] [Abstract][Full Text] [Related]
5. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis.
Okawa T; Okawa M; Koike T
J Bone Miner Metab; 2022 Nov; 40(6):960-967. PubMed ID: 35939236
[TBL] [Abstract][Full Text] [Related]
7. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis.
Okubo N; Matsui S; Matsumoto T; Sugimoto T; Hosoi T; Osakabe T; Watanabe K; Takami H; Shiraki M; Nakamura T
Calcif Tissue Int; 2020 Dec; 107(6):559-566. PubMed ID: 32839843
[TBL] [Abstract][Full Text] [Related]
8. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
[TBL] [Abstract][Full Text] [Related]
9. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
[TBL] [Abstract][Full Text] [Related]
10. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
Ebina K; Etani Y; Tsuboi H; Nagayama Y; Kashii M; Miyama A; Kunugiza Y; Hirao M; Okamura G; Noguchi T; Takami K; Goshima A; Miura T; Fukuda Y; Kurihara T; Okada S; Nakata K
Osteoporos Int; 2022 Aug; 33(8):1807-1813. PubMed ID: 35362725
[TBL] [Abstract][Full Text] [Related]
11. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
[TBL] [Abstract][Full Text] [Related]
13. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
14. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
[TBL] [Abstract][Full Text] [Related]
15. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD
Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
[TBL] [Abstract][Full Text] [Related]
16. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
17. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
[TBL] [Abstract][Full Text] [Related]
18. Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism.
Eller-Vainicher C; Palmieri S; Cairoli E; Goggi G; Scillitani A; Arosio M; Falchetti A; Chiodini I
J Am Geriatr Soc; 2018 Mar; 66(3):518-524. PubMed ID: 29364518
[TBL] [Abstract][Full Text] [Related]
19. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Leder BZ; Tsai JN; Jiang LA; Lee H
Bone; 2017 May; 98():54-58. PubMed ID: 28286299
[TBL] [Abstract][Full Text] [Related]
20. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
